| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC20724 | AZD-3161 | AZD-3161 is a potent and selective sodium channel Nav1.7 blocker for treatment of nociceptive pain. . |
|
| DC20129 | AZD3229 Featured | AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. |
|
| DC12265 | AZD3229 Tosylate | AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. |
|
| DC9946 | Lanabecestat(AZD3293,LY-3314814) | AZD3293 is a potent and selective orally active, brain-permeable BACE1 inhibitor,currently in development as a potential treatment for early Alzheimer’s disease. |
|
| DC7074 | AZD-3463 Featured | AZD-3463 is an ALK/IGF1R inhibitor which overcomes multiple mechanisms of acquired resistance to crizotinib. |
|
| DC5013 | AZD3514 | AZD3514 is a potent and oral androgen receptor with Ki of 2.2 μM and has ability of reducing AR protein expression. |
|
| DC8472 | AZD-3759 Featured | AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. |
|
| DC8400 | AZD3839 Featured | AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1. |
|
| DC9263 | AZD-3965 Featured | AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM. |
|
| DC8060 | AZD-3988 | AZD-3988 is a potent and selective diacylglycerol acyltransferase (DGAT-1) inhibitor (IC50 = 0.6 nM). |
|
| DC20725 | AZD 4017 | AZD4017 is a potent, selective, and orally bioavailable human 11β-HSD1 with IC50 of 7 nM, shows no significant activity against 11β-HSD1 and 17β-HSD1, 17β-HSD3 (IC50>30 uM). |
|
| DC23282 | AZD 4320 | AZD4320 is a BH3 mimetic and dual Bcl-2/Bcl-XL inhibitor with IC50 of <1 nM. |
|
| DC1075 | AZD4547 Featured | AZD4547 is a novel selective FGFR inhibitor targeting FGFR1, FGFR2, and FGFR3 with IC50 of of 0.2 nM, 2.5 nM, and 1.8 nM, respectively. |
|
| DC11295 | AZD-4573 | AZD4573 is a CDK9 inhibitor with an IC50 of <3 nM extracted from patent US 20160376287 A1, example 14. |
|
| DC10739 | AZD4635 Featured | AZD4635 is a novel adenosine 2A receptor (A2AR) inhibitor with a Ki of 1.7 nM. |
|
| DC23436 | AZD-4818 | AZD-4818 is a highly potent, selective CCR1 antagonist with pIC50 of 8.6, inhibits chemotaxia of human monocytes to MIP-1α in a concentration-dependent manner. |
|
| DC10773 | AZD5069 Featured | AZD-5069 is a potent and selective CXCR2 antagonist with the potential to inhibit neutrophil migration into the airways in patients with COPD. |
|
| DC10288 | AZD5153 6-Hydroxy-2-naphthoic acid Featured | AZD5153 6-Hydroxy-2-naphthoic acid is the 6-Hydroxy-2-naphthoic acid of AZD5153. AZD5153 is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor; disrupts BRD4 with an IC50 of 1.7 nM. |
|
| DC10774 | AZD5153 Featured | AZD5153 is a potent bivalent triazolopyridazine based Bromodomain and Extraterminal (BET) Inhibitor. |
|
| DC20727 | AZD-5248 | AZD-5248 is a potent, selective, first generation, oral inhibitor of dipeptidyl peptidase 1 (DPP1).. |
|
| DC7368 | AZD5363 Featured | AZD5363, a novel pyrrolopyrimidine-derived compound, inhibits all AKT isoforms (IC50 <10 nM). |
|
| DC7369 | AZD5438 Featured | AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM. It is less potent to CDK5/6. |
|
| DC20716 | AZD5576 | AZD5576(AZD 5576) is a potent, highly selective, and orally bioavailable inhibitor of CDK9 with IC50 of < 5 nM, decreases phosphorylation of Ser2-RNAPII in cells with an IC50 of 96 nM. |
|
| DC8232 | AZD5582 Featured | AZD5582 is a novel class of dimeric Smac mimetics as potent IAP antagonist; binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP (IC50 = 15, 21, and 15 nM, respectively). |
|
| DC7075 | AZD-5597 | AZD-5597 is potent CDK inhibitor with in vitro anti-proliferative effects against a range of cancer cell lines. |
|
| DC22009 | AZD5718 Featured | AZD5718 (AZD-5718, AZD 5718) is a novel potent 5-lipoxygenase activating protein (FLAP) inhibitor with binding IC50 of 6.3 nM; exhibits LTB4 inhibition in human whole blood assays with IC50 of 39 nM; reduce the production of pro-inflammatory and vasoactive leukotrienes both in vitro and in vivo. |
|
| DC20728 | AZD-5718 | AZD-5718 is an orally available small molecule, 5-lipoxygenase activating protein (FLAP) inhibitor.. |
|
| DC22007 | AZD5904 | AZD5904 (AZD-5904) is a potent, selective irreversible, orally bioavailable myeloperoxidase (MPO) inhibitor with IC50 of 140 nM, similar potency in mouse and rat. |
|
| DC12553 | AZD6088 | AZD6088 (AZD-6088) is a potent and selective, orally bioavailable partial agonist of the M1 muscarinic receptor, reduces heat hyperalgesia in SNL rats with an EC50 of 46.6 nM.. |
|
| DC1069 | AZD6244 (Selumetinib,ARRY-142886) Featured | AZD6244 (Selumetinib, ARRY-142886) is highly potent to inhibit MEK1 with IC50 of 14 nM. |
|
